Ligands of the GABA(A) receptor benzodiazepine binding site

CNS Drug Reviews

Volumn 5, Issue 2, 1999, Pages 125-144

  Wang, Qinmi ^a   Han, Yifan ^a   Xue, Hong ^a  

^a HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Hong Kong)

Author keywords

Benzodiazepine binding site ligand; GABA(A) receptor; Pharmacophore model; Structure activity relationship; Structure efficacy relationship

Indexed keywords

2 (4 CHLOROPHENYL) 5H PYRAZOLO[4,3 C]QUINOLIN 3 ONE; 2 (4 METHOXYPHENYL) 5H PYRAZOLO[4,3 C]QUINOLIN 3 ONE; 2 PHENYL 5H PYRAZOLO[4,3 C]QUINOLIN 3 ONE; 4 AMINOBUTYRIC ACID A RECEPTOR; 4 METHOXYMETHYL 5 (1 METHYLETHOXY) BETA CARBOLINE 3 CARBOXYLIC ACID ETHYL ESTER; 5 BENZYLOXY 4 METHOXYMETHYL BETA CARBOLINE 3 CARBOXYLIC ACID ETHYL ESTER; 5 ISOPROPOXY 4 METHYL BETA CARBOLINE 3 CARBOXYLIC ACID ETHYL ESTER; 6 BENZYLOXY 4 METHOXYMETHYL BETA CARBOLINE 3 CARBOXYLIC ACID ETHYL ESTER; 8 AZIDO 5,6 DIHYDRO 5 METHYL 6 OXO 4H IMIDAZO[1,5 A][1,4]BENZODIAZEPINE 3 CARBOXYLIC ACID ETHYL ESTER; BENZODIAZEPINE DERIVATIVE; BETA CARBOLINE DERIVATIVE; CHOLINESTERASE INHIBITOR; DIAZEPAM; FLAVONOID; IMIDAZOQUINOLINE DERIVATIVE; IMIDAZO[1,2 A]PYRIMIDINE DERIVATIVE; IMIDAZO[2,1 B]BENZOTHIAZOLE DERIVATIVE; LIGAND; PANADIPLON; PYRAZOLO[4,5 C]QUINOLIN 4 ONE DERIVATIVE; QUINOXALINE DERIVATIVE;

DRUG BINDING SITE; DRUG EFFICACY; DRUG RECEPTOR BINDING; LIGAND BINDING; PHARMACOPHORE; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW;

EID: 0032825862     PISSN: 1080563X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3458.1999.tb00094.x     Document Type: Review

References (74)

1. A receptors. Trends Pharmacol Sci 1995;16:162-168.
2. A receptor subunit. Nature 1997;385:820-823.
3. A receptors. TIPS 1997;18:425-429.
4. A receptor channels. Ann Rev Neurosci 1994; 17:569-602.
5. A receptor subtypes really occur in the brain? TINS 1996;19:139143.
6. A receptor subtypes. Pharmacol Rev 1995;47(2):181-234.
7. Gardner CR. Functional in vivo correlates of the benzodiazepine agonist-inverse agonist continuum. Prog Neurobiol 1988;31:425-476.
8. Gardner CR, Tully WR, Hedgecock CJR. The rapidly expanding range of neuronal benzodiazepine receptor ligands. Prog Neurobiol 1993;40:1-61.
9. Allen MS, Tan Y-C, Trudell ML, et al. Synthetic and computer-assisted analyses of the pharmacophore for the benzodiazepine receptor inverse agonist site. J Med Chem 1990;33:2343-2357.
10. Villar HO, Davies MF, Loew GH, Maguire PA. Molecular models for recognition and activation at the benzodiazepine receptor: A review. Life Sci 1991;48:593-602.
11. Diaz-Arauzo H, Koehler KF, Hagen TJ, Cook JM. Synthetic and computer-assisted analysis of the pharmacophore for agonist at benzodiazepine receptors. Life Sci 1991;49:207-216.
12. Schove LT, Perez JJ, Loew GH. Molecular determinants of recognition and activation at the cerebellar benzodiazepine receptor site. Bioorg Med Chem 1994;2:1029-1049.
13. Zhang W, Koehler KF, Zhang P, Cook JM. Development of a comprehensive pharmacophore model for the benzodiazepine receptor. Drug Des Dis 1995;12:193-248.
14. Fryer RI, Leimgruber W, Trybulski K. Quinazolines and 1,4-benzodiazepines. 90. Structure activity relationship between substituted 2-amino-N-(2-benzoyl-4-chlorophenyl)acetamides and 1,4-benzodiazepinones. J Med Chem 1982;25:1050-1055.
15. Borea PA, Bonora A. Brain receptor binding and lipophilic character of benzodiazepines. Biochem Pharmacol 1983;32:603-607.
16. Loew GH, Nienow JR, Poulsen M. Theoretical structure-activity studies of benzodiazepine analogues, requirements for receptor affinity and activity. Mol Pharmacol 1984;26:19-34
17. Ghose AK, Crippen GM. Modeling the benzodiazepine receptor binding site by the general three-dimensional structure-directed quantitative structure-activity relationship method. Mol Pharmacol 1990;37:725-734.
18. Greco G, Novellino E, Silipo C, Vittoria A. Study of benzodiazepine receptor sites using a combined QSAR-CoMFA approach. Quant Struct-Act Relat 1992;11:461-477.
19. Gupta SP, Saha RN, Mulchandani V. Quantitative structure-activity relationship studies on benzodiazepine receptor binding: Recognition of active sites in receptor and modelling of interaction. J Mol Recognit 1992;5:75-80.
20. A receptors using artificial neural networks. J Med Chem 1995;38:715-724.
21. A receptors. J Med Chem 1996;39:5246-5256.
22. Hasegawa K, Funatsu K. GA strategy for variable selection in QSAR studies: GAPLS and D-optimal designs for predictive QSAR model. J Mol Struct (Theochem) 1998;425:255-262.
23. Doble A, Martin IL, Richards DA. GABA modulation predicts biological activity of ligands for the benzodiazepine receptor. Br J Pharmacol 1982;76:238-244.
24. Wong G, Skolnick P. High affinity ligands for "diazepam-insensitive" benzodiazepine receptors. Eur J Pharmacol Mol Pharmacol Sec 1992;225:63-68.
25. 3H]Ro15-4513 binding sites. Eur J Pharmacol 1992;213:323-329.
26. Gu Z-Q, Wong G, Dominguez C, de Costa BR, Rice KC, Skolnick PI. Synthesis and evaluation of imidazo[1,5-a][1,4]-benzodiazepine esters with high affinities and selectivities at diazepam insensitive (DI) benzodiazepine receptors. J Med Chem 1993;36:1001-1006.
27. Wong G, Koehler KF, Skolnick P, et al. Synthetic and computer-assisted analysis of the structural requirements for selective, high-affinity ligand binding to diazepam-insensitive benzodiazepine receptors. J Med Chem 1993;36:1820-1830.
28. A receptors. J Med Chem 1995;38:1679-1688.
29. Zhang F, Koehler KF, Zhang P, Cook JM. Development of a comprehensive pharmacophore model for the benzodiazepine receptor. Drug Des Dis 1995;12:193-248.
30. Sharma RC, Singh P, Ojha TN. Oxadiazolylimidazobenzodiazepines as novel partial agonists with the benzodiazepine receptor - a QSAR analysis. Res Commun Chem Pathol Pharmacol 1993;80:357-362.
31. Martin LL, Tegeler JJ. Anti-anxiety agents and anticonvulsants. Ann Rep Med Chem 1988;23:19-28.
32. Watjen F, Baker R, Engelstoff M, et al. Novel benzodiazepine receptor partial agonists: Oxadiazolylimidazo-benzodiazepines. J Med Chem 1989;32:2282-2291.
33. Braestrup C, Nielsen M, Olsen CE. Urinary and brain beta-carboline-3-carboxylates as potent inhibitors of brain benzodiazepine receptors. Proc Natl Acad Sci USA 1980;77:2288-2292.
34. Allen MS, Hagen TJ, Trudell ML, Codding PW, Skolnick P, Cook JM. Synthesis of novel 3-substituted carbolines as benzodiazepine receptor ligands: Probing the benzodiazepine receptor pharmacophore. J Med Chem 1988;31:1854-1861.
35. Guzman F, Cain M, Larscheid P, et al. Biomimetic approach to potential benzodiazepine receptor agonists and antagonists. J Med Chem 1984;27:564-570.
36. Dorey G, Poissonnet G, Potier M-C, et al. Synthesis and benzodiazepine receptor affinities of rigid analogs of 3-carboxy-beta-carbolines-demonstration that the benzodiazepine receptor recognizes preferentially the s-cis conformation of the 3-carboxy group. J Med Chem 1989;32:1799-1804.
37. Lawson JA, Uyeno ET, Nienow J, Loew GH, Toll L. Structure-activity studies of beta-carboline analogs. Life Sci 1984;34:2007-2013.
38. Hagen TH, Skolnick P, Cook JM. Synthesis of 6-substituted β-carbolines that behave as benzodiazepine receptor antagonists or inverse agonists. J Med Chem 1987;30:750-753.
39. Hollinshead SP, Trudell ML, Skolnick P, Cook JM. Structural requirements for agonist actions at the benzodiazepine receptor: studies with analogues of 6-(benzyloxy)-4-(methoxymethyl)-β-carboline-3-carboxylic acid ethyl ester. J Med Chem 1990;33:1062-1069.
40. Allen MS, LaLoggia AJ, Dorn LJ, et al. Predictive binding of β-carboline inverse agonists and antagonists via the CoMFA/GOLPE approach. J Med Chem 1992;35:4001-4010.
41. Sharma RC, Ojha TN, Tiwari S, Singh P. Quantitative structure-activity relationship study of some benzodiazepine-receptor ligands having inverse agonist/antagonist and agonist actions. Drug Des Dis 1992;9:135-143.
42. Hadjipavlou-Litina D, Hansch C. Quantitative structure-activity relationships of the benzodiazepines -A review and reevaluation. Chem Rev 1994;94:1483-1505.
43. Fryer RI, Wang C-G, Chia N-C, Basile AS, Gu Z-Q, Skolnick P. Benzodiazepine-receptor (BZR) ligands: The conformational fit of agonist β-carbolines to an imidazobenzodiazepine template. Med Chem Res 1995;5:296-307.
44. Borea PA, Gilli G, Bertolasi V, Ferretti V. A stereochemical model accounting for receptor binding affinity and intrinsic activity of β-carbolines. Br J Pharmacol 1986;86:666.
45. Shannon HE, Hagen TJ, Guzman F, Cook JA. β-carbolines as antagonists of the discriminative stimulus effects of diazepam in rats. J Pharmacol Exp Ther 1988;246:275-281.
46. Previero A, Castellano C, Scuri R, Bianchi M, Rizzoli AA, Galzigna L. Synthesis and some properties of a homologous series of β-carboline-3-carboxylic esters. Farmaco 1989;44:435-441.
47. Malatynska E, Knapp R, Ikeda M, Yamamura HI. β-Carboline interactions at the BZ-GABA receptor chloride ionophore complex in the rat cerebral cortex. Brain Res Bull 1989;22:845-848.
48. Andrews J, Stephens DN. The discriminative stimulus properties of the β-carboline ZK95962: A non-sedating benzodiazepine receptor ligand with anxiolytic-like properties. Psychopharmacology (Suppl) 1988;96:354-354.
49. Yokoyama N, Ritter B, Neubert AD. 2-Arylpyrazolo[4,3-c]quinoline-3-ones: Novel agonist, partial agonist and antagonist of benzodiazepines. J Med Chem 1982;25:337-339.
50. Fryer RI, Zhang P, Rios R, Gu ZQ, Basile AS, Skolnick P. Structure-activity relationship studies at the benzodiazepine receptor (BZR): A comparison of the substituent effects of pyrazoloquinolinone analogs. J Med Chem 1993;36:1669-1673.
51. Cooper SJ, Kirkham TC, Estall LB. Pyrazoloquinolines: Second generation benzodiazepine receptor ligands have heterogeneous effects. Trends Pharmacol Sci 1987;8:180-184.
52. A receptors. Br J Pharmacol 1987;91:601-608.
53. Bennett DA. Pharmacology of the pyrazolo-type compounds: Agonist, antagonist and inverse agonist actions. Physiol Behav 1987;41:241-245.
54. Savini L, Massarelli P, Nencini C, et al. High affinity central benzodiazepine receptor ligands: Synthesis and structure-activity relationship studies of a new series of pyrazolo[4,3-c]quinolin-3-ones. Bioorg Med Chem 1998;6:389-399.
55. A receptors. Mol Pharmacol 1992;42:294-301.
56. A/benzodiazepine receptor. J Med Chem 1994;37:758-768.
57. Jacobsen EJ, TenBrink RE, Stelzer LS, et al. High-affinity partial agonist imidazo[1,5-a]quinoxaline amides, carbamates, and ureas at the γ-aminobutyric acid A/benzodiazepine receptor complex. J Med Chem 1996;39:158-175.
58. Mickelson JW, Jacobsen EJ, Carter DB, et al. High-affinity γ-aminobutyric acid A/benzodiazepine ligands: Synthesis and structure-activity relationship studies of a new series of tetracyclic imidazoquinoxalines. J Med Chem 1996;39:4654-4666.
59. A/benzodiazepine receptor complex. J Med Chem 1996;39:3820-3836.
60. Gupta SP, Paleti A. Quantitative structure - Activity relationship studies on benzodiazepine receptor binding of some nonbenzodiazepine series of ligands. Quant Struct-Act Relat 1996;15:12-16.
61. Miksicek RJ. Commonly occurring plant flavonoids have estrogenic activity. Mol Pharmacol 1993;44: 37-43.
62. A receptors in vitro. Drug Dev Res 1997;41:99-106.
63. Medina JH, Viola H, Wolfman C, et al. Overview-flavonoids: A new family of benzodiazepine receptor ligands. Neurochem Res 1997;22:419-425.
64. Marder M, Viola H, Wasowski C, et al. 6-Bromoflavone, a high affinity ligand for the central benzodiazepine receptors is a member of a family of active flavonoids. Biochem Biophys Res Comm 1996;223:384-389.
65. Marder M, Zinczuk J, Colombo MI, et al. Synthesis of halogenated/nitrated flavone derivatives and evaluation of their affinity for the central benzodiazepine receptor. Bioorg Med Chem Lett 1997;7:2003-2008.
66. Viola H, Wasowski C, Levi N, et al. Apigenin, a component of Mutricaria recutita flowers is a central benzodiazepine receptors-ligand with anxiolytic effects. Planta Med 1995;61:213-216.
67. Wolfman C, Viola H, Paladini AC, Dajas F, Medina JH. Possible anxiolytic effects of chrysin, a central benzodiazepine receptor-ligand isolated from Passiflora-coerulea. Pharmacol Biochem Behav 1994;47:1-4.
68. Häberlein H, Tschiersch K-P, Schäfer HL. Flavonoids from Leptospermum scoparium with affinity to the benzodiazepine receptor characterized by structure activity relationships and in vivo studies of a plant extract. Pharmazie 1994;49:912-922.
69. Clements-Jewery S, Danswan G, Gardner CR, et al. (Imidazo[1,2-a]pyrimidin-2-yl)-phenylmethanones and related compounds as potential nonsedative anxiolytics. J Med Chem 1988;31:1220-1226.
70. Tully WR, Gardner CR, Westwood R. General approach leading to the development of imidazoquinoline and imidazopyrimidine benzodiazepine receptor ligands. Drug Dev Res 1991;22:279-208.
71. Gardner CR, Budhram P, Deacon RMJ, Thomson TA. The relationship between structure and efficacy at central benzodiazepine receptors of a series of imidazopyrimidines and imidazoquinolines. Drug Dev Res 1991;22:309-320.
72. Gardner CR. Pharmacological profiles of non-benzodiazepine ligands for central benzodiazepine receptors. Clin Neuropharmacol (Suppl 2) 1990;13:555-556.
73. Gardner CR, Budhram P. Effects of agents which interact with central benzodiazepine binding sites on stress-induced ultrasounds in rat pups. Eur J Pharmacol 1987;134:275-283.
74. A receptor containing key ligand-binding residues overexpressed in Escherichia coli. Protein Sci 1998;7:216-219.